SVR12 of 99% Achieved With a Ribavirin-Free Regiment of ABT-450/r/Ombitasvir...
PRESIDENT’S PLENARY SESSION 1 Monday, October 20 8:00 am – 9:00 am (Terrace Ballroom) Moderators: Harry E. Sarles, Jr., MD, FACG John R. Saltzman, MD, FACG Oral 4: SVR12(sustained virologic response 12...
View ArticleSVR12 of 99% Achieved With a Ribavirin-Free Regiment of ABT-450r Ombitasvir...
Oral 4: SVR12 (sustained virologic response 12 weeks post-treatment) of 99% Achieved With a Ribavirin-Free Regiment Author Insight from Andreas Maieron, MD, Elisabeth Hospital, Linz, Austria What’s new...
View ArticleNormalization of Liver-Related Laboratory Parameters in HCV Genotype...
Oral 5: Normalization of Liver-Related Laboratory Parameters in HCV Genotype 1-Infected Patients With Cirrhosis After Treatment With ABT-450/R/Ombitasvir, Dasabuvir and Ribavirin Author insight from...
View ArticleACG 2014 Virtual Press Briefing: Hepatitis C
This year the College offers a series of pre-recorded virtual press briefings which feature the insights of leading gastroenterology experts on several key abstracts that will be unveiled at ACG 2014...
View ArticleStudy Suggests All-Oral Therapy for HCV G1 Patients is Highly Effective,...
Oral 65 High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/R+dasabuvir+/-Ribavirin: Integrated...
View ArticleStudy Suggests Alternative to Common HCV Treatment with Equally High SVR, No...
Poster 413 Efficacy of Ombitasvir/Paritaprevir/ and Dasabuvir +/-Ribavirin in Patients Receiving Concomitant Acid-Reducing Agents in Phase 3 Trials Author Insight from Mitchell L Shiffman, MD, FACG,...
View Article